Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tolerability, pharmacokinetics and effects on urinary glucose excretion of TS 071 administered as multiple ascending doses in male Japanese volunteers

Next Previous
Trial Profile

Tolerability, pharmacokinetics and effects on urinary glucose excretion of TS 071 administered as multiple ascending doses in male Japanese volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 22 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Luseogliflozin (Primary)
  • Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
  • Focus Pharmacokinetics; Therapeutic Use
  • Sponsors Taisho Pharmaceutical

Most Recent Events

  • 18 Feb 2014 Results published in the Advances in Therapy.
  • 04 Jul 2011 New trial record
  • 28 Jun 2011 Results presented at the 71st Annual Scientific Sessions of the American Diabetes Association.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top